SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

INDEX SEARCH RESULT

2021.06.25 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children - HTML (w)

2021.06.24 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) - HTML (w)

2021.06.18 | 18:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline - HTML (w)

2021.06.15 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio - HTML (w)

2021.06.14 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

CLARIANT

puce Clariant completes its divestment program by reaching agreement to divest its Pigments business - HTML (w)

2021.06.11 | 09:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria - HTML (w)

2021.06.11 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia - HTML (w)

2021.06.11 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) - HTML (w)

2021.06.08 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home - HTML (w)

2021.06.06 | 12:06 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) - HTML (w)

2021.06.04 | 15:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC - HTML (w)

2021.06.04 | 15:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy - HTML (w)

2021.06.04 | 14:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

ROCHE

puce Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma - HTML (w)

2021.06.03 | 23:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera - HTML (w)

2021.06.03 | 18:04 | Permanent Information Releases / General Company News

English version HTML (w) Mail

NOVARTIS

puce Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000